Veryan Appoints Two Industry Veterans as Non-Executive Directors.
11 July 2012 – Vascular disease specialist Veryan has announced the appointments of Todd M. Pope and Jeffrey B. Jump as Non-Executive Directors. Both have many years’ experience of the medical device industry.
“We are delighted to have acquired the expertise and guidance of two such veteran medical device specialists as Todd and Jeff”, commented Veryan Chief Executive Chas Taylor. “The additional perspectives they can offer will be particularly valuable to us as we acquire late stage clinical data for our BioMimics 3D Stent and start to commercialise the device”.
Todd M. Pope is President and CEO of TransEnterix, Inc., an emerging medical device company with the potential to revolutionize minimally invasive surgery. Prior to joining TransEnterix, he was the Worldwide President of Cordis Corporation, a multi-billion dollar Johnson and Johnson business unit specialising in minimally invasive treatments for vascular disease, a role to which he was appointed in 2006. Prior to Cordis, Todd was Chief Executive Officer of Liquidia Technologies, a start-up company focused on the development of nanoparticles which enable the targeted drug delivery of medicines and vaccines. Before joining Liquidia Technologies, he held roles of increasing responsibilities in Sales and Marketing at Boston Scientific, rising to Vice President, Global Sales and Marketing, Neurovascular Division.
Jeffrey B. Jump is President of interventional cardiology specialists Biosensors, a position he has held since 2010. He joined the company in 2003 as President of its Netherlands subsidiary, and was rapidly promoted to Managing Director for the whole of Europe. In 2005 he took on the additional responsibilities of Senior Vice President Sales and Marketing for Europe, Middle East, Africa, India, North and South America. In 2007 he was also given global responsibility for clinical and regulatory activities. Jeff is also currently on the board of therapeutic hypothermia specialists BeneChill Inc., and PneumRx Inc., a company developing an innovative minimally-invasive treatment for emphysema. Prior to joining Biosensors, Jeff was CEO of medical simulation specialists Xitact, which was subsequently acquired by Mentice. Before this he held senior management roles with several medical device companies, including Embol-X Inc., Alliance Medical Technologies, Cardio Thoracic Systems (CTS), Haemonetics S.A. and Pfizer Hospital Products Group.
“I’m excited to be joining Veryan at this crucial phase in the company’s development”, said Jeff. “Peripheral vascular disease treatment is currently one of the fastest-growing segments of the cardiovascular device market, and Veryan’s BioMimics 3D stent technology offers significant potential advantages over the vascular stents which are currently available for peripheral use.”
Veryan is developing innovative solutions to improve the performance of vascular stents using the principles of biomimicry. Veryan’s BioMimics 3D™ stent technology involves adapting traditional straight stent designs to a three-dimensional helical shape, which more closely mimics the natural geometry of the human vascular system. BioMimics 3D technology is designed to enhance clinical performance by improving flow conditions in, and bio-mechanical performance of, stented vessels.
Pre-clinical studies have shown that BioMimics 3D stent technology may significantly reduce restenosis (the narrowing of stented arterial segments) and confer significant mechanical benefits: the BioMimics 3D stent is more flexible, kink and fracture resistant than conventional counterparts.
Veryan has completed enrolment in a pivotal randomised study, MIMICS, and intends to submit a CE Mark application for the BioMimics 3D stent later this year.
For further information, please visit: www.veryanmed.com
+44 7831 569940